Nobel Prize winner company type 1 diabetes therapy is about to enter clinical diabetes therapy what else

Article source: Medical Rubik's Cube Pro

Author: Li Yuan

On November 16, CRISPR Therapeutics and ViaCyte announced that Health Canada has approved the clinical trial application for VCTX210, and it is expected to start patient registration before the end of the year

CRISPR Therapeutics is a company founded by Emmanuelle Charpentier, winner of the 2020 Nobel Prize in Chemistry

Type 1 diabetes is an autoimmune disease.

Among the many candidate treatment strategies, replacing β cells destroyed by autoimmunity is considered the closest approach to "cure" type 1 diabetes

VCTX210, developed by ViaCyte and CRISPR, is a stem cell-derived β-cell replacement product and has the potential to be applied to all type 1 and type 2 diabetes that require insulin

The CyT49 pluripotent human stem cell line is designed and modified by CRISPR technology to have immune evasion and can avoid being destroyed by the patient's immune system

In recent years, various innovative therapies and new technologies for diabetes have emerged one after another

In June 2020, Science Translational Medicine reported a new type of diabetes cell therapy.

In May of this year, Nexturn Bio acquired a 50% stake in RosVivo Therapeutics, and the type 2 diabetes RNA therapy developed by RosVivo also surfaced

According to the research report of RosVivo, compared with liraglutide/smeglutide, RSVI-301 has excellent performance and significantly reduced side effects

Source: RosVivo

In addition, there have been many advances in the development of pancreatic islet cell subcutaneous transplantation technology/equipment, which will not be repeated here

Note: The original text has been deleted

Reference materials:

[1] CRISPR Therapeutics and ViaCyte, Inc.